Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2020 – Stockhouse

Added 18,488 New Subscribers in 4Q20 4Q20 Revenues Increased by 19.2% YoY to RMB299.9 Million ($42.4 Million) 4Q20 Operating Income Increased by 68.1% YoY to RMB149.3 Million ($21.1 Million) Non-GAAP Operating Income Up 58.7% YoY to RMB161.7 Million ($22.8 Million) Conference Call to be Held on June 30, 2020 at 8:00 a.m.

Read more
Bio Bank Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast- 2025 – Cole of…

Bio banks refers back to the repository that stores, collects, distributes human organic materials which includes plasma, blood, saliva, purified DNA and other bio specimens. Biological banks hold a file of private and fitness related facts including genetic statistics, health facts, way of life, and circle of relatives records for use it in health and scientific research

Read more
Label-free sensing of exosomal MCT1 and CD147 for tracking metabolic reprogramming and malignant progression in glioma – Science Advances

INTRODUCTION Glioma is the most common type of brain cancer that predominantly originates from neuroglial stem cells (1). Accumulating evidence has revealed that a key hallmark during the malignant progression of glioma is metabolic reprogramming toward aerobic glycolysis, known as the Warburg effect (2)

Read more
Century Therapeutics Announces Acquisition of Empirica Therapeutics – Business Wire

PHILADELPHIA--(BUSINESS WIRE)--Century Therapeutics today announced its acquisition of Empirica Therapeutics to leverage its iPSC-derived allogeneic cell therapies against glioblastoma (GBM). We are pleased to welcome the Empirica team to the Century family. Their deep expertise and unique capabilities will allow us to accelerate efforts to develop iPSC derived immune effector cell products designed to treat and potentially cure brain cancer, said Lalo Flores, PhD, Chief Executive Officer of Century Therapeutics

Read more
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute…

- FDA provides very specific guidelines to study iPSC-derived MSCs - Company intends to submit an IND application for its iMSC therapy for patients with ARDS associated with COVID-19 CRANFORD, N.J., June 26, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the Company has received a written response from the U.S

Read more
Exosome Therapeutic Market Size, 2020-New Technological Change Helping Market, Application, Driver, – PharmiWeb.com

Pune, Maharashtra, India, June 29 2020 (Wiredrelease) Data Bridge Market Research A New Business Intelligence Report released by Data Bridge Market Research with title Global Exosome Therapeutic Market size, share, growth, Industry Trends and Forecast 2027 has abilities to raise as the most significant market worldwide as it has remained playing a remarkable role in establishing progressive impacts on the universal economy.

Read more